A Study on Biochemistry and Biology of Prehypertension and the Risk of the Cardiometabolic Syndrome
Main Article Content
Abstract
Having a systolic BP between 120 and 139 mmHg and a diastolic BP between 85 and 89 mmHg classifies as prehypertension. Prehypertension is a new and growing risk factor for cardiovascular disease, and it exists on a continuum with hypertension. Abdominal obesity, high blood pressure, abnormal lipid profiles, and insulin resistance are all components of the cardiometabolic syndrome. Most people who have metabolic syndrome are very vulnerable, thus it's best to prevent the condition by changing their lifestyle and treating its particular symptoms. Several trials using dietary interventions have shown their efficacy in halting the development of hypertension and improving metabolic abnormalities. There are now many large-scale studies investigating antihypertensive medications for their potential to halt the progression of hypertension. Traditional risk factor evaluation is not as useful as early detection of cardiovascular disease in asymptomatic persons in determining the need for tailored preventive treatment.
Article Details
References
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289(19):2560-2572.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
Donato AJ, Black AD, Jablonski KL, Gano LB, Seals DR. Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell. 2008;7(6):805-812.
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293-302.
Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996; 275: 1571–1576.
van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000; 342: 1–8.
Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990; 335: 827–838.
MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335: 765–774.
Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993; 153: 598–615.